NEWS & EVENTS

CATCH UP WITH OUR LATEST NEWS

New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations

Data to be featured as oral and poster presentations at American Epilepsy Society…

Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference

THOUSAND OAKS, Calif., November 25, 2024 — Capsida Biotherapeutics (“Capsida”), a…

Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy

NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory…

FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy

Wholly owned first-in-class program anticipated to enter clinical trials in first…

New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations

CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for…

Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer

Promotion reinforces commitment to advancing our wholly owned gene therapy pipeline…

Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

THOUSAND OAKS, Calif., February 21, 2024 -- Capsida Biotherapeutics (“Capsida”)…

Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies

Strategic partnership leverages Capsida’s next-generation manufacturing…

Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa

THOUSAND OAKS, Calif., September 20, 2023 -- Capsida Biotherapeutics (“Capsida”)…

Capsida Biotherapeutics Announces Publication in Nature Nanotechnology Identifying Novel Capsid With Significantly Increased Brain Transduction

Foundational research by Capsida and Caltech demonstrates ability to engineer AAVs…

Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer

Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick…

AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

Partnership Combines AbbVie's extensive capabilities with Capsida's novel…

Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer

Hakim brings more than 25 years’ experience leading finance and exponential growth…

Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40

Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues…

Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer

Company creates chief operating officer role and appoints veteran manufacturing and…

PharmaVoice profiles Capsida CEO Peter Anastasiou

Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality…

Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO

Longtime industry executive Peter Anastasiou appointed Chief Executive Officer…

Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference

Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a…

Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

New 15,000 square-foot facility in Thousand Oaks will enable industry leading…

Capsida Appoints Swati Tole, M.D., as Chief Medical Officer

Clinical development leader will help advance Capsida’s breakthrough AAV gene…

Capsida Biotherapeutics Debuts with $140 Million of Capital

Versant, Westlake Village BioPartners launch next-generation gene therapy company…

EVENTS

Posters Presented at the ASGCT Annual Meeting

Los Angeles, California
May 2023

Optimization of a Versatile Downstream Process for Multiple Novel AAV Capsids That Demonstrates Improved Recovery

Sophia Petraki, Leandro Fernandez, Amit Mirchandani, Abagail Wells, Hari Acharya, Heidy Morales, Elissa Troisi, Jesse Granados, Emily Springfield

Exploring upstream process conditions to improve productivity for novel AAV Capsids

Heidy Morales, Elissa Troisi, Lysa-Anne Volpe, Erick Reyes-Ramirez, Garrett Garrido, Jenna Rodden, Jesse Granados, Hari Acharya

Development and Comparative Assessment of a Rapid, High-Throughput Method for Accurate Quantification of Host Cell DNA Impurities in Final Drug Product and Process Intermediates

Jesse Granados, Francesca Sanchez, Izamary Marquez, David Chu